Related Experiment Videos
Trisomy 6 as a primary karyotypic aberration in hematologic disorders
A N Mohamed1, M L Varterasian, S M Dobin
1Wayne State University Detroit Medical Center, Detroit, Michigan, USA.
Cancer Genetics and Cytogenetics
|November 3, 1998
Summary
Trisomy 6 is a key genetic marker in certain blood disorders. This chromosomal abnormality may indicate a new subtype of myelodysplastic syndromes, particularly when associated with low blood counts.
Area of Science:
- Hematology
- Cytogenetics
- Oncology
Background:
- Trisomy 6 is a rare chromosomal abnormality.
- Its role in myeloid disorders is not well-defined.
Purpose of the Study:
- To investigate the significance of trisomy 6 in hematologic disorders.
- To determine if trisomy 6 represents a primary anomaly in myeloid malignancies.
Main Methods:
- Karyotypic analysis of bone marrow aspirates and peripheral blood.
- Clinical and pathological evaluation of seven adult patients with trisomy 6.
Main Results:
- Trisomy 6 was the sole karyotypic aberration in all seven patients.
- Three patients presented with cytopenia and hypocellular bone marrow, one later developing acute myeloid leukemia (AML-M1).
- Four patients were diagnosed with AML (French-American-British M1 or M4).
Conclusions:
- Trisomy 6 appears to be a nonrandom numerical anomaly in myeloid disorders.
- The combination of cytopenia, hypocellular bone marrow, and trisomy 6 may define a new variant of myelodysplastic syndromes.